Fiche traitement
Antiepileptic Drug
University of Aberdeen • Épilepsie
Suivi actif
À vérifier
Résumé
Antiepileptic Drug est développé par University of Aberdeen. Le traitement est actuellement en À vérifier. Il est associé à Épilepsie. . Le statut actuel est : suivi actif.
À vérifier
Non renseigné
À vérifier
University of Aberdeen
Non renseigné
People with epilepsy are predisposed to having seizures ("fits"), where abnormal electrical activity in the brain disrupts normal brain functioning. It is a common condition with around 1% of the population of Scotland having this condition. They are treated with anti-seizure medications, drugs which reduce the chance of having seizures.
Unfortunately, people with epilepsy are more likely to have severe infections than those without epilepsy and this is known to increase risk of seizures. The reasons for more severe infections in people with epilepsy are unclear, but one factor may be that anti-seizure medications impair the function of the body's immune system, which fights infection. The investigators' previous work looking at residents in the North-East of Scotland showed a link between these medications and risk of infection.
The investigators plan to study people being started on antiseizure medications (ASMs) with a new diagnosis of epilepsy and those already on ASMs with an established diagnosis of epilepsy in NHS Grampian. The investigators will compare with people not taking ASMs in a group of people with a single seizure and in a group of people with migraine.
The investigators will investigate immune function and infection risk with more-detailed information about individual's background, their seizures/epilepsy, other health conditions, and blood tests. The investigators will then do laboratory experiments to determine how ASMs may impair the immune system by looking at the function of types of white blood cells that play an important part in immune functioning.
The investigators also wish to develop statistical tools which can identify an individual's risk of infection when starting ASMs, based on their demographic, medical and social characteristics, to target closer monitoring/changes in treatment to those with higher risk.
This research will allow healthcare professionals to provide better individualised care in terms of which medication to use for treatment, what doses to use and whether blood tests to screen for impaired immune function would be helpful. The aim is that this will lead to reduced risk of infections in people with epilepsy, resulting in better outcomes in this condition.
2026-10-29
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
À vérifier
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Confiance automatique : 59%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : immune → Immunomodulation
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT07903168, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Contrôle de cohérence : 85/100
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-10-29
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréeÀ vérifier
Études associées1
Publications associées13
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
18 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2026-07-08 | PublicationProgress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). | Epilepsy research |
| 2026-07-08 | PublicationA review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures. | Therapeutic advances in neurological disorders |
| 2026-07-14 | PublicationAn Unusual Genetic Variant of Long QT Syndrome with Late Presentation in the Sixth Decade. | The Journal of innovations in cardiac rhythm management |
| 2026-08-08 | PublicationEpileptic Encephalopathy After Human Herpes Virus 6-Related Post-Transplant Acute Limbic Encephalitis in Children: A Case Report and Review of the Literature. | Cureus |
| 2026-08-08 | PublicationLacosamide Use After Traumatic Brain Injury: A Scoping Review. | Cureus |
| 2026-08-13 | PublicationAntiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study. | The Lancet. Neurology |
| 2026-08-16 | PublicationVoltage-gated sodium channels in the nervous system: Molecular physiology to therapeutic interventions. | Neural regeneration research |
| 2026-08-16 | PublicationA phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects . | International journal of clinical pharmacology and therapeutics |
| 2026-08-16 | PublicationPotassium Channelopathies and Precision Medicine Approaches in Epilepsy: A Systematic Review of Personalized Treatment Strategies. | Current neuropharmacology |
| 2026-08-16 | PublicationProgress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development. | Epilepsia |
| 2026-08-16 | PublicationClinical drug-oriented design, synthesis, and pharmacological evaluation of novel dual-target antiepileptic hybrid molecules. | Bioorganic chemistry |
| 2026-08-16 | PublicationEffect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. | International journal of clinical pharmacology and therapeutics |
| 2026-08-16 | PublicationAntiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades. | Drugs |
| 2026-10-29 | Dernière mise à jour des donnéesAntiepileptic Drug | Biomedical Watch |
| 2026-11-01 | Début de l’étudeNCT07903168 | Registre d’essai clinique |
| 2026-11-01 | Création de l’enregistrementNCT07903168 | Registre d’essai clinique |
| 2026-11-08 | Dernière mise à jour du registreNCT07903168 | Registre d’essai clinique |
| 2038-05-01 | Fin de l’étude prévue / enregistréeNCT07903168 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT07903168 | Epi-IRIS — Why Do People With Epilepsy Get More Infections? | À vérifier | NOT_YET_RECRUITING | Non communiqué | University of Aberdeen |
Publications liées
13 publication(s)Publications liées
13 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Voltage-gated sodium channels in the nervous system: Molecular physiology to therapeutic interventions. Voir source | 40808385 | 10.4103/NRR.NRR-D-25-00260 | Neural regeneration research | |
| A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects . Voir source | 30336805 | 10.5414/CP203276 | International journal of clinical pharmacology and therapeutics | |
| Potassium Channelopathies and Precision Medicine Approaches in Epilepsy: A Systematic Review of Personalized Treatment Strategies. Voir source | 42003125 | 10.2174/011570159X407197251204124232 | Current neuropharmacology | |
| Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development. Voir source | 42470359 | 10.1002/epi.70346 | Epilepsia | |
| Clinical drug-oriented design, synthesis, and pharmacological evaluation of novel dual-target antiepileptic hybrid molecules. Voir source | 42385394 | 10.1016/j.bioorg.2026.110159 | Bioorganic chemistry | |
| Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Voir source | 18397682 | 10.5414/cpp46119 | International journal of clinical pharmacology and therapeutics | |
| Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades. Voir source | 41764707 | 10.1007/s40265-026-02297-y | Drugs | |
| Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study. Voir source | 42586099 | 10.1016/S1474-4422(26)00216-4 | The Lancet. Neurology | |
| Epileptic Encephalopathy After Human Herpes Virus 6-Related Post-Transplant Acute Limbic Encephalitis in Children: A Case Report and Review of the Literature. Voir source | 40546590 | 10.7759/cureus.84647 | Cureus | |
| Lacosamide Use After Traumatic Brain Injury: A Scoping Review. Voir source | 42558887 | 10.7759/cureus.112117 | Cureus | |
| An Unusual Genetic Variant of Long QT Syndrome with Late Presentation in the Sixth Decade. Voir source | 42405015 | 10.19102/icrm.2026.17064 | The Journal of innovations in cardiac rhythm management | |
| Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Voir source | 19008076 | 10.1016/j.eplepsyres.2008.09.005 | Epilepsy research | |
| A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures. Voir source | 26136845 | 10.1177/1756285615589711 | Therapeutic advances in neurological disorders |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-10-29
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.